<DOC>
	<DOCNO>NCT01951430</DOCNO>
	<brief_summary>The purpose study observe number new case infection per population give time period characteristic pathology ( myelodysplastic syndrome , MDS ) involve ineffective production ( dysplasia ) class blood cell .</brief_summary>
	<brief_title>Observational Evaluation Infective Risk Myelodysplastic Syndrome Patients</brief_title>
	<detailed_description>The scarcity inadequacy data make impossible write evidence-based recommendation prevention management infection myelodysplastic syndrome . The aim study evaluate incidence spectrum infection MDS patient . Will also evaluate potential risk factor . This study could help definition optimal management MDS patient term prophylaxis infective complication term correct administration growth factor .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>All adult patient ( &gt; 18 year ) newly diagnose myelodysplastic syndrome patient undergone bone marrow reevaluation ; Signed write informed consent ; Psychiatric patient ; Patients life expectancy less three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adult patient</keyword>
	<keyword>Infective event</keyword>
	<keyword>Antibiotic</keyword>
	<keyword>Antifungal</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
</DOC>